Stewart Cole – President, Institut Pasteur, France
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Address: Institut Pasteur
25,28 rue du Docteur Roux
75724 Paris CEDEX 15 – FRANCE
,France
Tel: 33 (0)1 45 68 80 00
Web: http://www.pasteur.fr/ip/easysite/pasteur/en
Since its creation in 1887, the Institut Pasteur has become famous throughout the world as a symbol of science and french culture. For 120 years, our foundation has been contributing to the prevention and treatment of infectious diseases through research, teaching and public health initiatives.
Across the globe, thousands of researchers who have been trained or are working at Institut Pasteur share the values which form the very core of the Pasteurian community: an original scientific approach, an ongoing preoccupation with applying research to public health needs, professional ethics, a desire to care for people regardless of their background or nationality, and an outward-looking attitude, sharing knowledge and expertise with the international community. These guiding principles make the Institut Pasteur a unique institution which values exchanges and partnerships.
The Institut Pasteur enjoys an independent status and has numerous other assets, with its research laboratories, technological platforms, teaching centre and medical centre all located on one campus in the heart of Paris. It also has an international network which currently counts 30 members spread over the five continents.
With its unique setup and prestigious history, the Institut Pasteur has always stood at the forefront of innovation, adapting to the rapidly developing world of biological research and its applications, in particular in the field of biotechnology.
Nowadays, the Institut Pasteur has four priorities to carry out its activities successfully :
– to target its scientific strategy towards infectious diseases, microbiology, virology and immunology;
– to adopt an outward-looking attitude, both within France, through agreements and collaborations with its partners : CNRS (French National Scientific Research Centre), Inserm (French National Institute for Health and Medical Research), universities, hospitals, industrial partners, etc., and at international level with the development of the Réseau International des Instituts Pasteur (International Network of the Institut Pasteur or RIIP), which counts 30 institutes;
– to implement transversal research programs on ambitious themes and led by young researchers;
– to preserve the foundation’s independence, in particular through increased resources from sponsorship and donations.
These priorities, upholding the traditional tasks and values of the Institut Pasteur, place it at the cutting edge of the 21st century’s scientific and human challenges.
Scientific Research in infectious diseases, microbiology, virology and immunology
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Dr. Zoubir Harrat heads the Institut Pasteur d’Algérie (IPA), after having spent most of his career with the institution. He talks of the importance to prepare for the healthcare challenges…
Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of…
Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven…
Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive…
In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare…
David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service…
Dr Marc-Alexander Burmeister, president of B. Braun in France, shares the exciting changes to come for B. Braun globally and in France, and discusses the shifting environment of healthcare in…
Françoise Alliot-Launois, VP of the French League Against Rheumatism (AFLAR), discusses the issues around bone and joint infections in France, AFLAR’s work to help patients suffering from these diseases, and…
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Abbvie France’s Pierre-Claude Fumoleau outlines his strategic priorities for the affiliate, AbbVie’s unique corporate culture and ethos, and how he envisions upcoming regulatory reforms playing out in France. We…
Denis Delval, CEO of iconic French pharma firm LFB since December 2017, discusses his key priorities to build the new LFB. My vision is that we should be strong…
Biotest’s Olivier Samama outlines the changes that the takeover of the company has had on the French affiliate, the country’s plasma market and pricing policy. The product offering remains…
See our Cookie Privacy Policy Here
